Currently, only 44 percent of adults in the United States receive an annual flu vaccination. Though the rate has increased in recent years, the change has been slow and marginal. But, a new study suggests that a simple behavioral economics technique known as “active choice” may be able to help.
Experts from the Perelman School of Medicine at the University of Pennsylvania will be presenting data on the latest advances in cancer research and treatment at the AACR’s Annual Meeting in Washington, D.C. from April 1-5. Watch this space for press releases as embargoes lift during the meeting.
The American Association of Plastic Surgeons have recognized two renowned members of the Division of Plastic Surgery at the Perelman School of Medicine at the University of Pennsylvania as the Clinician and Mentor of the Year.
Penn Medicine will host Mind Your Brain, a free event offering insights on the latest brain injury research and therapies from Penn Medicine neuroscience and neurology and brain injury.
Current federal anti-kickback laws prohibit pharmaceutical companies and providers from bribing patients to seek their goods and services but prevent hospitals from offering services that could potentially benefit patients. In an essay published today in the New England Journal of Medicine, researchers call for a recrafting of these laws to permit more sensible health-promoting initiatives.
George M. Shaw, MD, PhD, has received $16.3 million over five years from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a long-sought-after HIV vaccine.
James Eberwine, PhD, has received the 2017 Scientific Innovations Award from the Chicago-based Brain Research Foundation, which supports research for preventing and treating neurological diseases.
Researchers have discovered a method that appears to provide earlier warning of organ transplant rejection compared to standard methods, and requires only a blood test rather than a more invasive and painful needle biopsy.
Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania.
In a new study, researchers have found that the utilization rates of certain potentially life-saving medications are low, particularly in the sub-group of pulmonary embolism patients who are critically ill.
For Patients and the General Public: